These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31168673)

  • 21. The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy.
    Gulcebi MI; Kendirli T; Turgan ZA; Patsalos PN; Onat Yilmaz F
    Epilepsy Res; 2018 Dec; 148():17-22. PubMed ID: 30326332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype.
    Rassu M; Biosa A; Galioto M; Fais M; Sini P; Greggio E; Piccoli G; Crosio C; Iaccarino C
    J Cell Mol Med; 2019 Dec; 23(12):8505-8510. PubMed ID: 31560168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
    Shi J; Zhou F; Wang LK; Wu GF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broadening the phenotypic spectrum of the presumably epilepsy-related SV2A gene variants.
    Badura-Stronka M; Kuszel Ł; Wencel-Warot A; Cudnoch K; Wołyńska K; Rutkowska K; Steinborn B; Płoski R
    Epilepsy Res; 2023 Feb; 190():107101. PubMed ID: 36758444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
    Chonan M; Saito R; Kanamori M; Osawa SI; Watanabe M; Suzuki H; Nakasato N; Tominaga T
    Neurol Med Chir (Tokyo); 2020 Jan; 60(1):37-44. PubMed ID: 31748440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events.
    Jalihal V; Shankar R; Henley W; Parrett M; Tittensor P; McLean BN; Ahmed A; Sander JW
    Epilepsy Behav; 2018 Mar; 80():365-369. PubMed ID: 29415871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brivaracetam for the treatment of epilepsy.
    Schulze-Bonhage A
    Expert Opin Pharmacother; 2011 Aug; 12(12):1959-66. PubMed ID: 21682662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of psychiatric and behavioral adverse effects of antiepileptic drugs monotherapy: Could they have a neuroendocrine correlation in persons with epilepsy?
    Sarangi SC; Kaur N; Tripathi M
    Epilepsy Behav; 2019 Nov; 100(Pt A):106439. PubMed ID: 31574428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare protein sequence variation in SV2A gene does not affect response to levetiracetam.
    Dibbens LM; Hodgson BL; Helbig KL; Oliver KL; Mulley JC; Berkovic SF; Scheffer IE
    Epilepsy Res; 2012 Sep; 101(3):277-9. PubMed ID: 22551666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children With Epilepsy.
    Kim MJ; Yum MS; Yeh HR; Ko TS; Lim HS
    J Clin Pharmacol; 2018 Dec; 58(12):1586-1596. PubMed ID: 30052270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study.
    Liguori C; Izzi F; Manfredi N; D'Elia A; Mari L; Mercuri NB; Fabio P
    Epilepsy Behav; 2018 Mar; 80():173-176. PubMed ID: 29414548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.
    Cardona AF; Rojas L; Wills B; Bernal L; Ruiz-Patiño A; Arrieta O; Hakim EJ; Hakim F; Mejía JA; Useche N; Bermúdez S; Carranza H; Vargas C; Otero J; Mayor LC; Ortíz LD; Franco S; Ortíz C; Gil-Gil M; Balaña C; Zatarain-Barrón ZL
    J Neurooncol; 2018 Jan; 136(2):363-371. PubMed ID: 29177594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life.
    Maschio M; Dinapoli L; Sperati F; Pace A; Fabi A; Vidiri A; Muti P
    J Neurooncol; 2011 Aug; 104(1):205-14. PubMed ID: 21107994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors.
    Newton HB; Dalton J; Goldlust S; Pearl D
    J Neurooncol; 2007 Sep; 84(3):293-6. PubMed ID: 17431542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [
    Xiao L; Xiang S; Chen C; Zhu H; Zhou M; Tang Y; Feng L; Hu S
    Psychiatry Clin Neurosci; 2024 Aug; 78(8):456-467. PubMed ID: 38804583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levetiracetam resistance: Synaptic signatures & corresponding promoter SNPs in epileptic hippocampi.
    Grimminger T; Pernhorst K; Surges R; Niehusmann P; Priebe L; von Lehe M; Hoffmann P; Cichon S; Schoch S; Becker AJ
    Neurobiol Dis; 2013 Dec; 60():115-25. PubMed ID: 24018139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.